Canary Wharf

NHS Artificial Intelligence provider reports 160% growth, promising to transform healthcare with better data

Wednesday, September 15, 2021 - 4:59pm

LONDON, Sept. 15, 2021 /PRNewswire/ -- RwHealth , the leading provider of Artificial Intelligenceto the healthcare industry, has reported 160%year-on-year growth as its data-led solutions are increasingly embraced by NHS trusts, private healthcare providers and pharmaceutical companies.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ -- RwHealth , the leading provider of Artificial Intelligenceto the healthcare industry, has reported 160%year-on-year growth as its data-led solutions are increasingly embraced by NHS trusts, private healthcare providers and pharmaceutical companies.
  • RwHealth's Data Science Platform combines Artificial Intelligence (AI)andMachine Learning to give healthcare providers in-depth data to make better decisions and improve patient outcomes.
  • By using RwHealth's analytical capabilitiesto make predictions, model treatment options, improve safety and increase efficiency, clinicians can deliver better, more widespread care.
  • In September 2020, NHSX , the organisation driving digital transformation inhealth and social care, announced a 250m investment into AI in UK healthcare.

Fisher Investments Recognised by Association of Talent Development as 2021 BEST Award Winner

Monday, September 13, 2021 - 11:07pm

CAMAS, Wash., Sept. 13, 2021 /PRNewswire/ -- Fisher Investments—the US-based parent company of Fisher Investments UK—was recognised by the Association for Talent Development (ATD) as a 2021 BEST Award winner for the third consecutive year. Fisher Investments was among 71 global organisations recognised by ATD for exceptional employee development. ATD, the world's largest professional talent development association, represents private and public organisations and executives in over 120 countries across every industry.

Key Points: 
  • CAMAS, Wash., Sept. 13, 2021 /PRNewswire/ --Fisher Investmentsthe US-based parent company of Fisher Investments UK was recognised by the Association for Talent Development (ATD) as a 2021 BEST Award winner for the third consecutive year.
  • Fisher Investments was among 71 global organisations recognised by ATD for exceptional employee development.
  • "We are honoured ATD has recognised our employee development efforts again this year," said Fisher Investments CEO Damian Ornani.
  • About Fisher Investments UK and Fisher Investments Europe Limited:
    Fisher Investments UK is the trading name of Fisher Investments Europe Limited and is part of the global group of Fisher companies.

UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

Friday, July 9, 2021 - 11:30am

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), today announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in June 2021, has been accepted by the United Kingdoms (UKs) Medicines and Healthcare Products Regulatory Agency (MHRA) for expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), today announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in June 2021, has been accepted by the United Kingdoms (UKs) Medicines and Healthcare Products Regulatory Agency (MHRA) for expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.
  • We are grateful this submission will receive expedited consideration by MHRA, said Cameron Durrant, CEO of Humanigen.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.

PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab

Thursday, June 17, 2021 - 1:00pm

The agreement covers countries in the European Union and European Economic Area, as well as the United Kingdom, Russia, Ukraine and other countries within the Commonwealth of Independent States.

Key Points: 
  • The agreement covers countries in the European Union and European Economic Area, as well as the United Kingdom, Russia, Ukraine and other countries within the Commonwealth of Independent States.
  • PhaseBio will be responsible for developing bentracimab and securing approval with the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), after which marketing authorization will be assigned to Alfasigma.
  • The signing of this commercialization agreement with our new partner, Alfasigma, is a truly momentous occasion for PhaseBio, said Jonathan P. Mow, Chief Executive Officer of PhaseBio Pharmaceuticals.
  • We share a high degree of enthusiasm with PhaseBio as we look forward to building the global bentracimab brand across Europe and other key markets.

BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

Friday, April 30, 2021 - 2:21pm

HAE patients in France currently have access to ORLADEYO through an Autorisation Temporaire d'Utilisation de cohorte (cohort ATU).\nIn the United Kingdom, HAE patients also currently have access to ORLADEYO through an approved early access to medicines scheme (EAMS).

Key Points: 
  • HAE patients in France currently have access to ORLADEYO through an Autorisation Temporaire d'Utilisation de cohorte (cohort ATU).\nIn the United Kingdom, HAE patients also currently have access to ORLADEYO through an approved early access to medicines scheme (EAMS).
  • A marketing authorization application (MAA) has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA).
  • The most frequently reported adverse reactions in patients receiving ORLADEYO compared with placebo were gastrointestinal reactions.
  • These reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.\nHAE patients note a significant treatment burden associated with existing prophylactic therapy.

EBA announces timing for the launch of its 2021 EU-wide stress test exercise

Monday, January 25, 2021 - 4:05pm

25 January 2021

Key Points: 

25 January 2021

The European Banking Authority (EBA) will launch its 2021 EU-wide stress test exercise with the publication of the macroeconomic scenarios on 29 January at 18:00 CET.

The EBA expects to publish the results of the exercise by 31 July 2021.

EBA releases erratum of the taxonomy package on reporting framework 3.0 phase 1

Thursday, January 14, 2021 - 4:10pm

The European Banking Authority (EBA) published today an erratum of the technical package on the reporting framework 3.0 phase 1.

Key Points: 
  • The European Banking Authority (EBA) published today an erratum of the technical package on the reporting framework 3.0 phase 1.
  • The corrections are mainly on the taxonomy files in the COREP NSFR module and COREP LR module where the EBA has addressed the issue of non-reportable data points on columns 0020 and 0030 of tables C 84, and amended a member code for Cash pooling arrangements in C 47.

Georgians for the Arts presents 2021 Annual Georgia Arts Action Summit & Arts Advocacy Week February 7-12, 2021

Saturday, January 9, 2021 - 11:40pm

SAVANNAH, Ga., Jan. 9, 2021 /PRNewswire/ --Georgians for the Arts presents the 2021 Georgia Arts Action Summit, which will be held virtually Sunday, February 7 and Monday, February 8, 2021, is a two-day digital event bringing together arts advocates from every corner of the State of Georgia.

Key Points: 
  • SAVANNAH, Ga., Jan. 9, 2021 /PRNewswire/ --Georgians for the Arts presents the 2021 Georgia Arts Action Summit, which will be held virtually Sunday, February 7 and Monday, February 8, 2021, is a two-day digital event bringing together arts advocates from every corner of the State of Georgia.
  • The event provides grassroots arts advocates training led by experienced advocates from throughout Georgia.
  • Arts advocates from throughout Georgia convene to hear presentations about the state of Georgian arts and culture, the latest arts policies, and upcoming related legislation impacting Georgia.
  • Arts Advocacy Week, scheduled from Monday, February 8 to Friday, February 12, 202, is dedicated time arts advocates from throughout Georgia schedule to meet with their elected Georgia legislative representatives to generate support for pro-arts issues.

EBA launches consultation to amend standards on benchmarking of internal models

Sunday, January 10, 2021 - 12:05am

17 December 2020

Key Points: 
  • 17 December 2020

    The European Banking Authority (EBA) published today a consultation paper proposing to amend the EU Commissions Implementing Regulation on the benchmarking of credit risk, market risk and IFRS9 models so as to include some new elements for the 2022 exercise.

  • The EBA benchmarking exercise forms the basis for both supervisory assessment and horizontal analysis of internal models.
  • Consultation process

    Responses to the consultations can be sent to the EBA by clicking on the "send your comments" button on the consultation page.

  • A public hearing on this consultation will take place on the 20 January 2021 from 11:00 to 13:00 CET.

EBA proposes appropriate methodology to calibrate O-SII buffer rates

Sunday, January 10, 2021 - 12:05am

22 December 2020

Key Points: 
  • 22 December 2020

    The European Banking Authority (EBA) proposed today the implementation of an EU-wide floor methodology to calibrate buffer rates of Other Systemically Important Institutions (O-SIIs).

  • The proposed methodology included in the Report aims at strengthening the stability of the banking sector and avoiding the under-calibration of O-SII capital buffer rates, while allowing the relevant authorities to consider national banking sector specificities.
  • National authorities will still retain the ability to set higher O-SII buffer rates than the prescribed floor and are encouraged to do so where deemed appropriate.
  • At the moment, there is no harmonised methodology at EU level to calibrate O-SII buffer rates.